Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03502434 · ClinicalTrials.gov registry record · Phase 1
A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers
A Phase 1 study, sponsored by Biosplice Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 223
- Enrollment target
NCT03502434 is a Phase 1 study that has completed, run by Biosplice Therapeutics. The registered enrollment target is 223 participants.
The verdict
NCT03502434, a Phase 1 study, has completed, sponsored by Biosplice Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 223 participants
- Enrollment target
Study Summary
This is a single center, randomized, controlled, within subject comparison, single dose study to determine the sensitization potential of SM04755 solution on normal skin under semi-occlusive patch conditions.
Interventions
- OTHER Vehicle
- OTHER Sodium lauryl sulfate
- OTHER White Petrolatum
- DRUG SM04755
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2017-09-11 |
| Est. Completion | 2017-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03502434
The ClinicalTrials.gov registry entry for NCT03502434 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosplice Therapeutics, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vehicle is the first listed.
NCT03502434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03502434 about?
NCT03502434 is a clinical study titled "A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers". This is a single center, randomized, controlled, within subject comparison, single dose study to determine the sensitization potential of SM04755 solution on normal skin under semi-occlusive patch conditions.
What is the current status of trial NCT03502434?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 223 participants. The study started on 2017-09-11. Estimated completion is 2017-11-17.
What interventions are being tested in trial NCT03502434?
The interventions under investigation include: Vehicle (OTHER), Sodium lauryl sulfate (OTHER), White Petrolatum (OTHER), SM04755 (DRUG).
Who is sponsoring clinical trial NCT03502434?
This trial is sponsored by Biosplice Therapeutics, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.